<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

The Development of HUB Organoids

development of HUB organoids and tumor organoids from Lgr5+ adult stem cells

development of HUB organoids and tumor organoids from Lgr5+ adult stem cellsReview the development and use of HUB Organoids, from the first discovery of Lgr5 as an adult stem cell biomarker in the Clevers lab, to the model features and data which have led to their widespread use today.

The History of Organoids

Researchers have tried to establish long term in vitro cultures of healthy human cells to study human development and morphogenesis since the late 1970s. The term ‘organoids’ became increasingly popular following the seminal works of Knoblich and Sasai. It’s currently used to signify 3D cell-based models derived from adult, embryonic, or induced pluripotent stem cells which are maintained in vitro to give rise to mini-organs.

Organoids represent the only in vitro technology to faithfully recapitulate original tissue physiology, providing a fast and cost-effective model for applications such as drug development and tissue engineering.

Adult Stem Cell Identification

It’s always been widely accepted that a pool of cells with self-renewing and differentiating properties was necessary for organ regeneration after damage. However, the identification of adult stem cells (aSCs) was elusive for a long time due to the lack of stem cell specific biomarkers.

The breakthrough came with the discovery of Lgr5 as an adult stem cell biomarker for the small intestine by the Clevers lab. This finding was a steppingstone to the development of new technology mastered by Hubrecht Organoid Technology (HUB) and the large-scale production of aSC-derived organoids.

This seminal publication identified Lgr5+ cells as the stem cells of the small intestine and colon, using knock-in mouse models combined with an in-depth understanding of intestinal homeostasis and cancer regulation. Further research showed that Lgr5 is the stem cell marker in several organs of epithelial origin, such as the stomach, liver, and pancreas.

Organoid Development

Following the identification of intestinal aSCs, the Clevers lab established in vitro gut organoid cultures, starting from single Lgr5+ stem cells. Each stem cell operates independently of positional environmental cues to generate a self-organizing epithelial structure which resembles the normal gut, continuously expands, and can be cultured long term. These expanding crypt cells undergo multiple crypt fission events to generate villus-like epithelial domains containing differentiated cell types. The aSC derived organoids are remarkably stable, both genotypically and phenotypically, and can be passaged for many years.

To prove stability upon culture, a large batch of organoids was grown from a single Lgr5 colon stem cell and transplanted orthotopically into colitis models with intestinal damage. The organoids readily integrated as functional intestinal epithelium patches that were indistinguishable from the surrounding normal epithelium.

The original organoid methods were adapted to generate organoids from many different organs. The components needed to grow mini-organs using this technology are fairly conserved and include:

  • a potent source of Wnt, as the Wnt pathway has emerged as the key player in maintaining the stem cell fate and driving stem cell proliferation
  • a potent activator of tyrosine kinase receptor signaling such as EGF, which exerts mitogenic effects on stem cells
  • inhibition of BMP/Tgfb signals which normally drive differentiation
  • Matrigel to mimic the extracellular environment

Small fragments of primary tissue can also be used as the starting material for organoid development. This is potentially because tissue fragmentation and culturing in a conditioned media can mimic the environment of a damage response in vivo. This can revert cells which have already committed to differentiation back into a stem cell state.

Developing a Living Biobank of Human Tissues

Once protocols for ‘normal’ tissue organoids were established, scientists at the HUB and other research centres refined the technology to grow organoids from primary human colon, prostate, and pancreatic cancers.

HUB researchers were the first to report on the generation of a large library of colorectal cancer (CRC) tumor organoids, defined as a ‘living biobank’ of patient-derived organoids (PDOs). PDOs provide the unique opportunity for functional drug testing such as sensitivity screening and correlating treatment data with the genetic make-up of individual tumors.

HUB Tumor Organoids: Robust and Reproducible In Vitro Models

Today HUB researchers have optimized protocols for deriving and maintaining 3D ex vivo organoids from both healthy and diseased tissues, and have developed large living biobanks of PDO from several organs. HUB Organoids have emerged as a robust preclinical platform for oncology drug development, with the Clevers lab/HUB protocols widely used and published by other research groups. This is due to a number of features and applications of HUB Organoids. For example, organoid stability is a key aspect that HUB researchers have leveraged to develop applications like large scale drug screens.

HUB tumor organoids also closely recapitulate several properties of the original tumor such as gene amplification, somatic copy number, and mutations. Each organoid represents their parental patient tumor, maintaining the genetic and phenotypic characteristics. Establishment of tumor organoids from 20 consecutive colorectal carcinoma patients showed several properties of the original tumors were closely mimicked.

Genetic information is also intact in living biobanks of CRC organoids. This genetic information matches with previous large scale mutational analyses of CRC, demonstrating that CRC major molecular subtypes are represented by tumor organoids. These features mean that HUB organoids are ideal for high-throughput drug screening to investigate gene-drug associations, and to complement cell line and xenograft studies.

Phenotypic and genetic profiling of a living biobank of HUB Organoids, derived from metastatic, colorectal cancer patients showed a degree of similarity to original patient tumors. Using these organoids in drug screening showed that response or non-response to an agent is associated with organoid molecular profile.

Other studies have also compared response from ex vivo organoid, PDO-based orthotopic mouse tumor xenograft models and cancer patients in clinical trials. These data showed that PDOs faithfully recapitulate patient response in the clinic and have the potential to be used as drug screening platform.

Summary

HUB protocols provide a solid base for the development of organoids, with strong scientific background to model development. Organoid establishment allows scientists to replace 2D, regular, very homogenous cell cultures and to use the platform as a stepping stone to more expensive and time consuming animal studies. HUB tumor organoids have emerged as a robust preclinical model to predict clinical outcomes in patients, providing enhanced oncology model options for drug development programs.


Related Posts